Vance G. Fowler, Jr., MD, MHS
Professor of Medicine
Duke University
Durham, North Carolina
Disclosure: Abbvie : Grant/Research Support (Status: Ongoing); Actavis : Grant/Research Support; Advanced Liquid Logics : Grant/Research Support; Affinergy : Consultant, Research Grant or Support; Affinium : Consultant; Allergan : Grant/Research Support; Ampliphi Biosciences : Consultant; Armata : Consultant (Status: Ongoing); Basilea : Consultant, Research Grant or Support; Bayer : Consultant, Consultant; C3J : Consultant; CARB-X : Consultant (Status: Ongoing); Cerexa : Consultant, Research Grant or Support; Contrafect : Consultant, Research Grant or Support; Cubist : Grant/Research Support; Debiopharm : Consultant; Destiny : Consultant; Durata : Consultant; Forest : Grant/Research Support; Genentech : Consultant, Research Grant or Support; ICBiome : Consultant (Status: Ongoing); Integrated Biotherapeutics : Consultant; Janssen : Consultant, Research Grant or Support; Karius : Grant/Research Support; Locus : Grant/Research Support; Medical Biosurfaces : Grant/Research Support; Medicines Co. : Consultant; Medimmune : Consultant, Research Grant or Support; Merck : Consultant, Research Grant or Support; NIH : Grant/Research Support; Novadigm : Consultant; Novartis : Consultant, Research Grant or Support; Pfizer : Grant/Research Support; Regeneron : Consultant, Research Grant or Support; Tetraphase : Consultant; Theravance : Consultant, Research Grant or Support; Valanbio : Board Member (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing); xBiotech : Consultant
